Asthma
Conditions
Keywords
Health Status Disparities, Minority Health, Pediatrics, Behavioral Intervention, Cellular Phone, Peer Group
Brief summary
This study has two main goals. The first goal is to test whether a mobile phone intervention can increase adherence to daily inhaled steroid medications in African American adolescents prescribed this type of medication by his/her asthma doctor. The second goal is to use a mobile phone intervention to better understand real life patterns of use of quick-relief (beta2-adrenergic agonist) asthma medication in this population.
Interventions
BEHAVIORALAsthma Supervision
Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
BEHAVIORALMobile Phone
Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
BEHAVIORALInhaled Corticosteroid Mobile Phone Application
The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
BEHAVIORALBeta2-adrenergic agonist Mobile Phone Application
The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
GlaxoSmithKline
Rush University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
11 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
* 11-16 years of age * self-identify as African American * have persistent asthma * be on a prescription daily inhaled corticosteroid medication for asthma * be on a prescription inhaled beta2-adrenergic agonist medication for asthma
Exclusion criteria
* candidate refusal * the presence of other co-morbidities that could interfere wtih study participation * \> 60% adherence to inhaled corticosteroid medication, measured by the electronic dose counter, during the run-in period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence to inhaled corticosteroids, measured objectively using an electronic dose counter | 10 weeks | Adherence is measured as the mean of daily adherence to prescription inhaled corticosteroid dose over 14 days both at baseline and at week 10 of the active treatment phase. For the primary outcome, we will compare adherence at week 10 to adherence at baseline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To understand patterns of use of quick-relief medication for asthma | 10 weeks | This study will use an electronic dose counter and mobile phone technology to track participants real time use of quick-relief (beta2-adrenergic agonist) medication for asthma during the 10 weeks of active treatment. |
Countries
United States
Outcome results
None listed